# A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

> **NCT04215653** · PHASE3 · UNKNOWN · sponsor: **Sihuan Pharmaceutical Holdings Group Ltd.** · enrollment: 448 (estimated)

## Conditions studied

- Duodenal Ulcer，DU

## Interventions

- **DRUG:** Anaprazole Sodium
- **DRUG:** Rabeprazole
- **DRUG:** Rabeprazole Placebo
- **DRUG:** Anaprazole Sodium Placebo

## Key facts

- **NCT ID:** NCT04215653
- **Lead sponsor:** Sihuan Pharmaceutical Holdings Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-20
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-28
- **Target enrollment:** 448 (ESTIMATED)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04215653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04215653, "A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04215653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*